{
    "clinical_study": {
        "@rank": "73672", 
        "arm_group": [
            {
                "arm_group_label": "SAR100842", 
                "arm_group_type": "Experimental", 
                "description": "Oral administration, twice daily, every day, for 8 weeks"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Oral administration,  of matching pills, twice daily, every day, for 8 weeks"
            }
        ], 
        "brief_summary": {
            "textblock": "Primary Objective:\n\n      - To evaluate safety and tolerability of 8-week oral administration of SAR100842 in patients\n      with diffuse, cutaneous systemic sclerosis.\n\n      Secondary Objectives:\n\n        -  To evaluate the pharmacodynamic effect of SAR100842 in patients with systemic sclerosis\n           as measured by disease related biomarkers and Lysophosphatidic acid (LPA) receptor\n           signaling markers in blood and skin\n\n        -  To explore the effect of SAR100842 on skin thickness in patients with systemic\n           sclerosis as measured by the Modified Rodnan Skin score (mRSS)\n\n        -  To explore the effect of SAR100842 on quality of life as measured by the Scleroderma\n           Modified Health Assessment Questionnaire (SHAQ)."
        }, 
        "brief_title": "Proof of Biological Activity of SAR100842 in Systemic Sclerosis", 
        "completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Systemic Sclerosis", 
        "condition_browse": {
            "mesh_term": [
                "Scleroderma, Systemic", 
                "Scleroderma, Diffuse", 
                "Sclerosis"
            ]
        }, 
        "detailed_description": {
            "textblock": "Each patient's participation in the study will be approximately 13 weeks: up to 2 weeks of\n      screening, 8 weeks of treatment and 3 weeks of follow up"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria :\n\n        - Patients who meet the American College of Rheumatology (ACR) criteria for systemic\n        sclerosis with diffuse cutaneous involvement and <36 months since the onset of the first\n        systemic sclerosis manifestation other than Raynaud's phenomenon and have a Modified\n        Rodnan Skin Score (mRSS) \u2265 15 and an area of definite involvement of the dorsal forearm\n        that is considered amenable to repeated 4mm skin biopsies.\n\n        Exclusion criteria:\n\n          1. Patients with high dose or unstable low dose  immunosuppressive drugs, cytotoxic,\n             anti-fibrotic or glucocorticoids drugs at least 4 weeks prior to screening\n\n          2. Serum creatinine > 2.0 mg/dL\n\n          3. Gastrointestinal involvement preventing oral administration of study drug\n\n          4. Severe cardiac and/or pulmonary disease\n\n        The above information is not intended to contain all considerations relevant to a\n        patient's potential participation in a clinical trial."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 24, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01651143", 
            "org_study_id": "ACT12339", 
            "secondary_id": [
                "2012-001369-34", 
                "U1111-1127-2854"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "SAR100842", 
                "description": "Pharmaceutical form:tablets\nRoute of administration: oral", 
                "intervention_name": "SAR100842", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Pharmaceutical form:tablets\nRoute of administration: oral", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "April 16, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Scottsdale", 
                        "country": "United States", 
                        "state": "Arizona", 
                        "zip": "85259-5499"
                    }, 
                    "name": "Investigational Site Number 840006"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Washington", 
                        "country": "United States", 
                        "state": "District of Columbia", 
                        "zip": "20007"
                    }, 
                    "name": "Investigational Site Number 840003"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Baltimore", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "21287"
                    }, 
                    "name": "Investigational Site Number 840004"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02118"
                    }, 
                    "name": "Investigational Site Number 840001"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ann Arbor", 
                        "country": "United States", 
                        "state": "Michigan", 
                        "zip": "48106"
                    }, 
                    "name": "Investigational Site Number 840002"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New Brunswick", 
                        "country": "United States", 
                        "state": "New Jersey", 
                        "zip": "08903"
                    }, 
                    "name": "Investigational Site Number 840007"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pittsburgh", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "15213"
                    }, 
                    "name": "Investigational Site Number 840008"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lille", 
                        "country": "France", 
                        "zip": "59037"
                    }, 
                    "name": "Investigational Site Number 250003"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Paris Cedex 14", 
                        "country": "France", 
                        "zip": "75679"
                    }, 
                    "name": "Investigational Site Number 250001"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Milano", 
                        "country": "Italy", 
                        "zip": "20122"
                    }, 
                    "name": "Investigational Site Number 380001"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Z\u00fcrich", 
                        "country": "Switzerland", 
                        "zip": "8091"
                    }, 
                    "name": "Investigational Site Number 756001"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "United Kingdom"
                    }, 
                    "name": "Investigational Site Number 826001"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Salford", 
                        "country": "United Kingdom", 
                        "zip": "M6 8HD"
                    }, 
                    "name": "Investigational Site Number 826002"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "France", 
                "Italy", 
                "Switzerland", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "Double-blind, Randomized, Placebo-controlled, 8-week Study Investigating the Safety, Pharmacokinetics and Pharmacodynamics of SAR100842 Given Orally to Patients With Diffuse Cutaneous Systemic Sclerosis", 
        "overall_official": {
            "affiliation": "Sanofi", 
            "last_name": "Clinical Sciences & Operations", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Safety and tolerability during the 8 week treatment period (Number of patients reporting adverse events)", 
            "safety_issue": "Yes", 
            "time_frame": "Up to 8 weeks"
        }, 
        "removed_countries": {
            "country": "Germany"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01651143"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Pharmacodynamic changes from baseline to End of Treatment Visit in biomarkers obtained from blood and skin", 
                "safety_issue": "No", 
                "time_frame": "at Day 1 and 8 weeks"
            }, 
            {
                "measure": "Change from baseline to End of Treatment Visit in skin severity score (mRSS) and in Scleroderma health assessment questionnaire (SHAQ)", 
                "safety_issue": "No", 
                "time_frame": "at Day 1 and 8 weeks"
            }
        ], 
        "source": "Sanofi", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Sanofi", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}